New Endpoints, Evaluation Standards Urged for Immuno-Oncology Trials

Clinical Trials Advisor
A A
Future cancer immunotherapy trials need new standardized endpoints and evaluation criteria, regulators and scientists said at an FDA workshop.

To View This Article:

Login

Subscribe To Clinical Trials Advisor